FIELD: chemistry.
SUBSTANCE: invention relates to field of biotechnology, in particular to cancer biomarkers, and can be used in medicine. Detection of Engrailed-2 (EN2) protein or thereof coding nucleic acid in sample of patient's urinary bladder or urine can be used in diagnostics of urinary bladder cancer or for identification of patient who has risk of urinary bladder cancer, as well as for monitoring of urinary bladder cancer progressing in patient or monitoring efficiency of urinary bladder cancer treatment.
EFFECT: invention makes it possible to apply EN2 in diagnostics of urinary bladder cancer.
10 cl, 5 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TTK PEPTIDES AND VACCINES CONTAINING THEM | 2010 |
|
RU2531348C2 |
| PHOSPHODIESTERASE 4D7 AS MARKER FOR AGGRESSIVE HORMONE-SENSITIVE PROSTATE CANCER | 2010 |
|
RU2575076C2 |
| ANTIBODIES AGAINST FGFR3 AND METHODS OF THEIR APPLICATION | 2010 |
|
RU2568066C2 |
| PHOSPHODIESTERASE 4D7 AS PROSTATE CANCER MARKER | 2010 |
|
RU2651474C2 |
| METHODS AND COMPOSITIONS FOR DIAGNOSTICS OF ANKYLOSING SPONDYLITIS WITH APPLICATION OF BIO-MARKERS | 2006 |
|
RU2438704C2 |
| MPHOSPH1 PEPTIDES AND VACCINES CONTAINING THEM | 2012 |
|
RU2612905C2 |
| MARKERS FOR ENDOMETRIAL CANCER | 2010 |
|
RU2596394C2 |
| MODIFIED MELK PEPTIDES AND VACCINES CONTAINING LATTER | 2011 |
|
RU2580035C2 |
| PHOSPHODIESTERASE 9A AS MARKER OF MALIGNANT TUMOR OF PROSTATE GLAND | 2010 |
|
RU2592668C2 |
| CD43 ANTIBODIES AND USE THEREOF FOR TREATING CANCER | 2016 |
|
RU2694903C1 |
